


IMbrave150 Study Design



Co-primary endpoints

- OS
- IRF-assessed PFS per RECIST 1.1

Secondary endpoints included:

- IRF-assessed ORR, DOR per RECIST 1.1 and HCC mRECIST^b
- PROs: TTD^c of QOL, physical and role functioning (EORTC QLQ-C30)
- Safety and tolerability assessed based on the nature, frequency and severity of AEs per NCI CTCAE version 4.0

^a Japan is included in rest of world. ^b Tumor assessment by computed tomography or magnetic resonance imaging was done at baseline and every 6 weeks until 54 weeks, then every 9 weeks thereafter.

^c Time from randomization to first decrease from baseline of ≥ 10 points maintained for 2 consecutive assessments or 1 assessment followed by death from any cause within 3 weeks.

AFP, α-fetoprotein; CTCAE, Common Terminology Criteria for Adverse Events; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer; IRF, independent review facility; mRECIST, modified RECIST; NCI, National Cancer Institute; PRO, patient-reported outcomes; QOL, quality of life; TTD, time to deterioration.